AiCuris logo
Startup

AiCuris

See AiCuris's full profile

BOOK A DEMO
Headquarters

Germany

Founded Year

2021

Total Funding

$74.8M

Employees

11 - 50

Status

Terminated


About AiCuris

AiCuris (from 'Anti-infective Cures' ) is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Headquarters

Wuppertal, Germany


General Information on AiCuris

Brand name AiCuris
Company name AiCuris Anti-infective Cures GmbH
Register number HRB 26180
Website https://www.aicuris.com/
Founded year 2021
Employees 11 - 50
Contact [email protected]
+49202317630

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about AiCuris

Archyworldys 10.04.2022
DGAP-News: AiCuris nominates Madam Therapeutics with its innovative peptide approach to combat antibiotic resistance as the inaugural winner of AiCubator Resident Status 2022

The issuer / publisher is responsible for the content of the notification. AiCuris nominates Madam Therapeutics with its innovative peptide approach to combat antibiotic resistance as the inaugural winner of AiCubator Resident Status 2022, an initiative to support new innovative projects, at the BIOCOM AMR Conference 2022 In the second year of the AiCubator initiative, an innovative, artificial intelligence-based approach by Madam Therapeutics ...

AiCuris news
Open PR 17.11.2021
APAC Cold Sore Treatment Market to Reflect Steadfast Expansion during 2021-2028 | GSK, Sun Pharma, Glenmark, Zydus, Cipla, AiCuris, HRA Pharma

Asia-Pacific Cold Sore Treatment Market Synopsis: The large scale Cold Sore Treatment Market report sheds light on each region, Market size in terms of (USD Mn) for every individual segment and their sub-segment for the period from 2021 to 2028, considering the macro and micro situation factors. The document gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the Market and ...

AiCuris news
Radio Wuppertal Online 25.10.2021
AiCuris testet Corona-Medikament

Das Wuppertaler Pharma-Unternehmen AiCuris arbeitet weiter an einem Corona-Medikament. Aktuell laufen die klinischen Studien dazu. Dafür Menschen werden untersucht, die frisch positiv getestet und ungeimpft sind. Die Studie findet allerdings nicht in Wuppertal statt, sondern in Berlin. Die Betroffenen verbringen ihre Quarantäne dann in den Räumen, wo die klinische Studie durchgeführt wird, sagt Firmenchef Holger Zimmermann. In einem halben Jahr ...

Pharmabiz.com 25.10.2021
AiCuris, Lysando expand existing collaboration to develop & optimize Artilysin-based drug candidates to treat diabetic foot infections

AiCuris and Lysando joined forces in 2019 to drive the fight against antimicrobial resistance, with innovative approaches based on Lysando’s Artilysin technology platform, a new class of phage-lysine derived artificial designer molecules with a novel mode of action and the potential to replace conventional antibiotics. Under the terms of the agreement, AiCuris received exclusive access to Lysando's technology to generate Artilysin for specific ...

Consorsbank 22.10.2021
DJ DGAP-News: AiCuris gibt Ausweitung der -2-

AiCuris wurde 2006 als Spin-Off der Bayer AG gegründet und konzentriert sich auf die Erforschung und Entwicklung von Wirkstoffen gegen Infektionskrankheiten. Hauptinvestor des Unternehmens ist die SANTO Holding. Mit PREVYMIS(TM) (Letermovir) wurde ein "First-in-Class" nicht-nukleosidischer Cytomegalovirus (CMV)-Inhibitor entwickelt, der seine Wirkung über einen neuartigen Wirkmechanismus entfaltet. Er wurde im Jahre 2012 an MSD auslizensiert und ...

Market Screener 22.10.2021
PRESS RELEASE : AiCuris announces expansion of its -2-

AiCuris Anti-infective Cures AG MC Services AG Katja Woestenhemke Dr. Solveigh Mähler Phone: +49 202 317 63 0 Phone: +49 211 529 252 19 Email: [email protected] Email: [email protected] Lysando AG Verena Schossmann Phone: +41 79 211 83 42 Email: [email protected] ^[1] https://www.who.int/health-topics/diabetes#tab=tab_1 ^[2] Murphy-Lavoie HM, Ramsey A, Nguyen M, et al. Diabetic Foot Infections. [Updated 2021 Jul 10]. ...

AiCuris news
Yahoo! Finance 22.10.2021
AiCuris Announces Expansion of its Collaboration with Lysando with a Focus on Diabetic Foot Infections

The new project will focus on the identification and optimization of Artilysin(R)s for the topical treatment of infected, chronic wounds, particularly wounds that fail to respond to conventional antiseptics or systemic antibiotics due to their location or the formation of drug-resistant microbial biofilms. Of note, in contrast to a systemic treatment, a topical formulation would also be beneficial in terms of antibiotic stewardship ...

AiCuris news